ADDM	active DNA demethylation;
AE	adverse event;
AID	activation-induced deaminase;
ATR	ataxia telangiectasia and Rad3–related kinase;
BER	base excision repair;
cHL	classical Hodgkin Lymphoma;
CMMRD	constitutional mismatch repair deficiency;
CR/PR	complete/partial response;
CRC	colorectal cancer;
ctDNA	circulating tumor DNA;
CTLA-4	cytotoxic T-lymphocyte–associated antigen 4;
DCR	disease control rate (CR + PR + stable disease);
DDM	DNA demethylation;
DLBCL	diffuse large B-cell lymphoma;
dMMR	deficient mismatch repair (MMRdeficient);
dPCR	digital polymerase chain reaction;
EC	endometrial cancer;
EXO1	exonuclease 1;
GE	gastroesophageal;
HeCOG	hellenic cooperative oncology group;
HR	hazard ratio;
ICI	immune checkpoint inhibitors;
IDL	insertion-deletion loops;
IHC	Immunohistochemistry;
IO	immunotherapy;
LS	lynch syndrome;
MAF	mutant allele frequencies;
mCRC	metastatic colorectal cancers;
MEF	mouse embryonic fibroblasts;
MGMT	methylguanine DNA methyltransferase;
MLH	MutL homolog;
MMR	mismatch repair;
MSH	MutS homolog;
MSI	microsatellite instability;
MSI-H	microsatellite instability high;
MSS	microsatellite stable;
MutLα	MLH1-PMS2;
MutSα	MSH2-MSH6;
NEC	Neuroendocrine Cancer;
NET	neuroendocrine tumors;
NGS	next-generation sequencing;
ORR	objective response rate;
OS	overall survival;
PCNA	proliferating cell nuclear antigen;
PCR	polymerase chain reaction;
PD-1/PD-L1	programmed cell death-1/its ligand;
PFS	progression-free survival
PINK1	PTEN-induced putative kinase 1;
PMBCL	primary mediastinal B-cell lymphoma;
pMMR	proficient MMR (MMR-intact);
POLβ	polymerase beta;
POLγ	polymerase gamma;
ROS	reactive oxygen species;
RPA	replication protein A;
SCE	sister chromatid exchange;
SHM	somatic hypermutation;
SS	synovial sarcomas;
TLS	post-translesion synthesis;
TMB	tumor mutational burden;
TMZ	Temozolomide;
UV	ultraviolet;
VUS	variants of unknown significance;